Florensocatib

Florensocatib
Clinical data
Other namesCHF-10196; HSK-31858
Identifiers
  • (2S)-N-[(1S)-1-cyano-2-[2-fluoro-4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC23H23FN4O4
Molar mass438.459 g·mol−1
3D model (JSmol)
  • CN1C2=C(C=CC(=C2)C3=CC(=C(C=C3)C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)F)OC1=O
  • InChI=InChI=1S/C23H23FN4O4/c1-28-19-11-15(5-6-20(19)32-23(28)30)14-3-4-16(18(24)10-14)9-17(12-25)27-22(29)21-13-26-7-2-8-31-21/h3-6,10-11,17,21,26H,2,7-9,13H2,1H3,(H,27,29)/t17-,21-/m0/s1
  • Key:ONJDRXNRBKHINH-UWJYYQICSA-N

Florensocatib is an investigational new drug that is being developed by Chiesi Farmaceutici S.p.A. for the treatment of bronchiectasis. It is a cathepsin C inhibitor.

References

  1. ↑ "Florensocatib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
  2. ↑ Thornton CS, Schaupp L, Tunney MM, Mall MA (June 2026). "Bridging the airway microbiome and targeted therapy in bronchiectasis: multi-omics insights, endotypes and emerging therapies". The European Respiratory Journal. doi:10.1183/13993003.00239-2026. PMID 42276744.